Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin

Takeshi Masuda,Xin Wang,Manami Maeda,Matthew C Canver,Falak Sher,Alister P W Funnell,Chris Fisher,Maria Suciu,Gabriella E Martyn,Laura J Norton,Catherine Zhu,Ryo Kurita,Yukio Nakamura,Jian Xu,Douglas R Higgs,Merlin Crossley,Daniel E Bauer,Stuart H Orkin,Peter V Kharchenko,Takahiro Maeda,Matthew C. Canver,Alister P. W. Funnell,Gabriella E. Martyn,Laura J. Norton,Douglas R. Higgs,Daniel E. Bauer,Stuart H. Orkin,Peter V. Kharchenko
DOI: https://doi.org/10.1126/science.aad3312
IF: 56.9
2016-01-15
Science
Abstract:Reactivating the fetal globin gene Mutation of adult-type globin genes causes sickle cell disease and thalassemia. Although treating these hemoglobinopathies with gene therapy is possible, there is a pressing need for pharmacologic approaches to treat general patient populations. One promising approach is to reactivate repressed expression of fetal-type hemoglobin (HbF) in adult erythroid cells. Masuda et al. reveal a molecular mechanism governing HbF repression as mediated by the LRF/ZBTB7A transcription factor. The study may encourage the development of new HbF reactivation therapies for hemoglobinopathies. Science , this issue p. 285
multidisciplinary sciences
What problem does this paper attempt to address?